Cinoxacin

DB00827ApprovedWithdrawnSmall molecule

Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.

Mechanism: Evidence exists that cinoxacin binds strongly, but reversibly, to DNA, interfering with synthesis of RNA and, consequently, with protein synthesis. It appears to also inhibit DNA gyrase. This enzyme is necessary for proper replicated DNA separation. By inhibiting this enzyme, DNA replication and cell division is inhibited.
Curator reviewed
Primary indication: For the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species (including K. pneumoniae), and Enterobacter species.Curator reviewed
Formula / weight: C₁₂H₁₀N₂O₅ · 262.2182 g/mol (avg)
Code names: 64716

Resolves to

Compound

UNIILMK22VUH23CAS28657-80-9ChEMBLCHEMBL1208ChEBI3716PubChem2762KEGGD00872

Clinical / RWD

RxNorm2550ATCJ01MB06PharmGKBPA449007

Structure

InChIKeyVDUWPHTZYNWKRN-UHFFFAOYSA-NSMILESCCN1N=C(C(O)=O)C(=O)C2=CC3=C(OCO3)C=C12

Targets

P43700gyrAQ02880TOP2BP11388TOP2A

Transporters

Q4U2R8SLC22A6

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

990Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

10Marketed productsAcross 1 country and 9 labellers

1ATC codeIncluding every combination product, plus 15 drug categories

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cinoxacin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In